• 1.

    Sukumar S, et al. Thrombotic thrombocytopenic purpura: Pathophysiology, diagnosis, and management. J Clin Med 2021; 10:536. doi: 10.3390/jcm10030536

  • 2.

    Little DJ, et al. Long-term kidney outcomes in patients with acquired thrombotic thrombocytopenic purpura. Kidney Int Rep 2017; 2:10881095. doi: 10.1016/j.ekir.2017.06.007

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Zheng XL, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020; 18:24862495. doi: 10.1111/jth.15006

  • 4.

    Zheng XL, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020; 18:24962502. doi: 10.1111/jth.15010

  • 5.

    Bendapudi PK, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: A cohort study. Lancet Haematol 2017; 4:e157-e164. doi: 10.1016/S2352-3026(17)30026-1

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Wynick C, et al. Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada. Thromb Res 2020; 196:335339. doi: 10.1016/j.thromres.2020.09.012

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Scully M, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019; 380:335346. doi: 10.1056/NEJMoa1806311

  • 8.

    Goshua G, et al. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021; 137:969976. doi: 10.1182/blood.2020006052

Thrombotic Thrombocytopenic Purpura International Society on Thrombosis and Haemostasis Guidelines for Diagnosis and Treatment

Anitha Vijayan Anitha Vijayan, MD, is Professor of Medicine, Division of Nephrology, Washington University in St. Louis, MO.

Search for other papers by Anitha Vijayan in
Current site
Google Scholar
PubMed
Close
Restricted access
Save